Citigroup Inc 908 Devices Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in 908 Devices Inc. stock. As of the latest transaction made, Citigroup Inc holds 20,671 shares of MASS stock, worth $45,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,671

Previous 5,323 288.33%

Holding current value

$45,476

Previous $27,000 162.96%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.45 - $6.17 $52,950 - $94,697	15,348 Added 288.33%	20,671 $71,000
Q2 2024 Aug 12, 2024	BUY	$5.0 - $7.24 $5,745 - $8,318	1,149 Added 27.53%	5,323 $27,000
Q1 2024 May 10, 2024	BUY	$6.55 - $9.92 $6,654 - $10,078	1,016 Added 32.17%	4,174 $31,000
Q4 2023 Feb 09, 2024	BUY	$4.96 - $12.41 $15,609 - $39,054	3,147 Added 28609.09%	3,158 $35,000
Q3 2023 Nov 09, 2023	SELL	$6.0 - $8.2 $39,114 - $53,455	-6,519 Reduced 99.83%	11 $0
Q2 2023 Aug 10, 2023	SELL	$5.78 - $10.02 $21,576 - $37,404	-3,733 Reduced 36.37%	6,530 $44,000
Q1 2023 May 11, 2023	BUY	$6.61 - $10.66 $63,733 - $102,783	9,642 Added 1552.66%	10,263 $88,000
Q4 2022 Feb 09, 2023	SELL	$7.0 - $17.96 $1,232 - $3,160	-176 Reduced 22.08%	621 $4,000
Q3 2022 Nov 10, 2022	SELL	$15.18 - $24.99 $22,815 - $37,559	-1,503 Reduced 65.35%	797 $13,000
Q2 2022 Aug 10, 2022	SELL	$13.3 - $20.74 $5,971 - $9,312	-449 Reduced 16.33%	2,300 $47,000
Q1 2022 May 12, 2022	SELL	$13.18 - $26.28 $42,004 - $83,754	-3,187 Reduced 53.69%	2,749 $52,000
Q4 2021 Feb 10, 2022	BUY	$23.17 - $38.77 $95,576 - $159,926	4,125 Added 227.77%	5,936 $154,000
Q3 2021 Nov 10, 2021	BUY	$29.99 - $39.13 $54,311 - $70,864	1,811 New	1,811 $59,000

Others Institutions Holding MASS

# of Institutions

Shares Held

18.4M

Call Options Held

14.1K

Put Options Held

22K

View Full List

About 908 Devices Inc.

Ticker MASS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 31,590,200
Market Cap $69.5M
Description
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-...

More about MASS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account